Patients with recurrent advanced-stage and/or metastatic cervical cancer typically have a poor prognosis with limited treatment options available. Now, data from the phase III innovaTV 301 trial demonstrate the efficacy of the tissue factor-targeted antibody–drug conjugate tisotumab vedotin in this setting.

A total of 502 patients with advanced-stage and/or metastatic cervical cancer who previously received 1 (62.8%) or 2 (36.8%) lines of therapy were randomly assigned (1:1) to receive tisotumab vedotin versus investigator’s choice of chemotherapy (including topotecan, vinorelbine, gemcitabine, irinotecan or pemetrexed). Overall survival (OS) was the primary end point.